Hello mooers, welcome to another week of the FDA calendar. Here are what happened last week and what's coming up this week. BIGGEST MOVERS FROM THIS WEEK The CEO of$CNS ファーマシューティカルズ(CNSP.US)$has disclosed the acquisition of 15,000 shares at a mean price of $0.69 per share. Shares closed the week down 20% at $1.89. $デルマタ セラピューティクス(DRMA.US)$received FDA approval for its proposed protocols and regulations for the Phase 3 clin...
6
1
報告
Joy Boy Myth :
this guy's good. why never post again...
MACRO US Economy Stalls as Credit Narrows, Fed's Beige Book Says The US economy stalled in recent weeks, with hiring and inflation slowing and access to credit narrowing, the Federal Reserve said in its Beige Book survey of regional business contacts. The Beige Book likely reinforces the chances that Fed policymakers will pause their run of interest-rate hikes following an expected quarter-point increase at the next ga...
$バンク オブ アメリカ(BAC.US)$ – The bank stock was about flat even after the firm reported first-quarter earnings and revenue that topped expectations. Its strong results were driven by higher rates as net interest income jumped 25% year over year. CEO Brian Moynihan said he sees a relatively mild recession in the U.S. $バンク オブ ニューヨーク メロン(BK.US)$ – The bank’s shares dropped 0.3% after a mixed first-quarter earnings report. While the bank’s earnings ca...
Hello mooers, welcome to another week of the FDA calendar. Here are what happened last week and what's coming up this week. Top Medical News of the Week Moderna and Merck to develop a cancer vaccine for high-risk melanoma patients Last week, we had some exciting news on cancer vaccine development announced by Moderna and Merck. Moderna's vaccine, based on its messenger RNA technology, is being studied in combination with Merck's Keytruda to treat...
Joy Boy Myth : this guy's good. why never post again...